**Question:** Atorvastatin is used as an anti-dyslipidemic drug. These drugs inhibit their target enzyme by

A. HMG-CoA reductase
B. Cytochrome P450
C. LDL receptors
D. Acyl-CoA cholesterol acyltransferase (ACAT)

**Correct Answer:** A. HMG-CoA reductase

**Core Concept:** HMG-CoA reductase, also known as 3-hydroxy-3-methylglutaryl-coenzyme A reductase, is an enzyme involved in the mevalonate pathway, a crucial step in cholesterol synthesis. Atorvastatin, a statin drug, is used to lower cholesterol levels and reduce cardiovascular risk.

**Why the Correct Answer is Right:** Atorvastatin is a specific inhibitor of HMG-CoA reductase. By blocking this enzyme, it prevents cholesterol synthesis in the liver, leading to increased excretion of cholesterol through bile and reduction in low-density lipoprotein (LDL) cholesterol levels. This results in improved lipid profiles and reduced cardiovascular risk.

**Why Each Wrong Option is Incorrect:**

A. HMG-CoA reductase is the correct target enzyme for statin drugs like atorvastatin, not Cytochrome P450 (B). Statins inhibit the enzyme to achieve their therapeutic effect, not by affecting Cytochrome P450, which is involved in drug biotransformation and clearance.

B. LDL receptors (C) do not directly relate to statin action. Statins lower LDL cholesterol by inhibiting HMG-CoA reductase, not by affecting LDL receptors.

D. Acyl-CoA cholesterol acyltransferase (ACAT) is involved in cholesterol esterification within cells and not directly related to cholesterol synthesis or statin action. Statins work by inhibiting HMG-CoA reductase, not ACAT.

**Clinical Pearl:** The correct understanding of statin action is essential for prescribing and explaining the benefits of these drugs to patients. Statins are a vital component of primary and secondary prevention of cardiovascular diseases, particularly in patients with hyperlipidemia or established coronary artery disease.